JOP20210098A1 - أجسام مضادة تتعرف على تاو - Google Patents

أجسام مضادة تتعرف على تاو

Info

Publication number
JOP20210098A1
JOP20210098A1 JOP/2021/0098A JOP20210098A JOP20210098A1 JO P20210098 A1 JOP20210098 A1 JO P20210098A1 JO P20210098 A JOP20210098 A JO P20210098A JO P20210098 A1 JOP20210098 A1 JO P20210098A1
Authority
JO
Jordan
Prior art keywords
antibodies recognizing
tau
recognizing tau
antibodies
specifically bind
Prior art date
Application number
JOP/2021/0098A
Other languages
English (en)
Inventor
Svetlana; Alexander
Robin; Barbour
Yue; Liu
Tarlochan S Nijjar
Iii Philip James; Dolan
Mark E Renz
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/059895 external-priority patent/WO2020096608A1/en
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of JOP20210098A1 publication Critical patent/JOP20210098A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يعمل هذا الاختراع على إعداد أجسام مضادة والتي ترتبط ارتباط معين مع تاو tau . تعمل الأجسام المضادة على تثبيط أو إبطاء مسببات الامراض التي ترتبط مع تاو والأعراض المرتبطة بها.
JOP/2021/0098A 2018-11-08 2019-11-08 أجسام مضادة تتعرف على تاو JOP20210098A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2018/059895 WO2020096608A1 (en) 2018-11-08 2018-11-08 Antibodies recognizing tau
US201862758421P 2018-11-09 2018-11-09
PCT/US2019/060616 WO2020097561A1 (en) 2018-11-08 2019-11-08 Antibodies recognizing tau

Publications (1)

Publication Number Publication Date
JOP20210098A1 true JOP20210098A1 (ar) 2023-01-30

Family

ID=70610738

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0098A JOP20210098A1 (ar) 2018-11-08 2019-11-08 أجسام مضادة تتعرف على تاو

Country Status (16)

Country Link
US (1) US20220153821A1 (ar)
EP (1) EP3877410A4 (ar)
JP (1) JP2022506719A (ar)
KR (1) KR20210090184A (ar)
CN (1) CN113454112A (ar)
AU (1) AU2019377595A1 (ar)
BR (1) BR112021008624A2 (ar)
CL (1) CL2021001158A1 (ar)
CO (1) CO2021007370A2 (ar)
IL (1) IL283049A (ar)
JO (1) JOP20210098A1 (ar)
MX (1) MX2021005411A (ar)
PE (1) PE20211777A1 (ar)
PH (1) PH12021551048A1 (ar)
SG (1) SG11202104549TA (ar)
WO (1) WO2020097561A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
SG11201809331RA (en) 2016-05-02 2018-11-29 Prothena Biosciences Ltd Antibodies recognizing tau
PE20190261A1 (es) 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN116925217B (zh) * 2023-09-14 2024-03-08 北京凯祥弘康生物科技有限公司 针对Tau蛋白的抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031698B1 (ru) * 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
DK2758433T3 (en) * 2011-09-19 2018-01-15 Axon Neuroscience Se PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE
PT2935326T (pt) * 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
EP3786182A1 (en) * 2014-11-19 2021-03-03 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
CA2986942A1 (en) * 2015-06-05 2016-12-08 Genentech, Inc. Anti-tau antibodies and methods of use
PE20190261A1 (es) * 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
EP3487524A4 (en) * 2016-07-20 2020-03-25 Anahit Ghochikyan HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES
PE20212324A1 (es) * 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau

Also Published As

Publication number Publication date
US20220153821A1 (en) 2022-05-19
MX2021005411A (es) 2021-07-06
AU2019377595A1 (en) 2021-05-27
CN113454112A (zh) 2021-09-28
CL2021001158A1 (es) 2021-11-26
BR112021008624A2 (pt) 2021-09-28
CO2021007370A2 (es) 2021-06-21
EP3877410A1 (en) 2021-09-15
EP3877410A4 (en) 2022-08-10
KR20210090184A (ko) 2021-07-19
SG11202104549TA (en) 2021-05-28
PH12021551048A1 (en) 2021-12-06
IL283049A (en) 2021-06-30
WO2020097561A1 (en) 2020-05-14
JP2022506719A (ja) 2022-01-17
PE20211777A1 (es) 2021-09-08

Similar Documents

Publication Publication Date Title
SA518400355B1 (ar) أجسام مضادة تتعرف على تاو
ZA201907819B (en) Antibodies recognizing tau
MX2021009440A (es) Anticuerpos que reconocen tau.
SA518400354B1 (ar) أجسام مضادة تتعرف على تاو
PH12021551048A1 (en) Antibodies recognizing tau
IL277072A (en) Anti-claudin antibodies 18.2
IL279321A (en) Anti-SIRPalpha antibody
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG11202106214YA (en) Novel anti-ccr8 antibody
AU2018448903A8 (en) Antibodies recognizing tau
SG10202111141WA (en) Anti-claudin 18.2 antibodies and uses thereof
MX2020010040A (es) Anticuerpos que se unen a tau y usos de los mismos.
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
BR112021016947A2 (pt) Anticorpos que reconhecem tau
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
WO2017075173A3 (en) Anti-factor d antibodies and conjugates
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
IL280239A (en) Enhanced clotting antibodies
GB201817172D0 (en) Antibody
MX2020010092A (es) Variantes de anticuerpo c-terminales.
WO2019133902A3 (en) Antibodies and assays for ccl14
MX2021010517A (es) Anticuerpos que reconocen tau.
EA202192113A1 (ru) Антитела, распознающие тау
GB201911931D0 (en) Anti-C7 antibody or antibody fragment